tDCS & Pain

Chronic Pain is one of the largest challenges facing healthcare providers today. Healthcare providers have few treatment options to choose from, each with potentially debilitating side-effects or low efficacy, leaving many patients with a poor quality of life.

Nuraleve Inc. has developed a novel chronic pain neuromodulation treatment program: Painrelief tC™. The treatment targets four segments of the chronic non-cancer pain market: Neuropathic Pain, Fibromyalgia, Chronic Migraine, and Chronic Regional Pain Syndrome (CRPS). The treatment is both preventive of Chronic Pain, and a treatment for Chronic Pain symptoms.

tDCS & Substance Abuse

Nuraleve Inc’s proprietary technology tDCS is an effective and safe program for treating substance addiction. Neuromodulation is a revolutionary new set of neuroplasticity techniques that can be used to modify the human brain. One such technique is called transcranial direct current stimulation (tDCS). Nuraleve has developed a platform technology and service, applying tDCS to reduce symptoms associated with addiction.

A promising feature of tDCS is its ability to induce neuroplasticity, engaging some of the same systems (e.g., dopamine, glutamate) that figure prominently in the pathological neuroplasticity caused by many addictive substances. Drug-induced neuroplasticity is thought to underlie the cravings for these substances, and by extension, the long-lasting vulnerability to relapse that characterizes addiction. By enhancing neuroplasticity, tDCS through its SMARTSTIM™ platform, offers the potential to reverse some of the motivational consequences of cravings, to reduce consumption, and to reduce the risk of relapse of addiction.